One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations.
Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. Globally, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases, glaucoma, and specifically cancer have a significant impact on the health status of people worldwide, with comparatively higher growth rates in developing countries.
MarketsandMarkets is providing a platform for pharmaceutical, biotechnology professionals and technology providers to come together at the BioGeNe 2022 Confex on the 16th - 17th June 2022 in San Diego-USA to discuss advancements and solutions to the most critical challenges in the Biomarker, Microbiome and Genome engineering areas.
With growing pressures of increasing success rates for FDA approved biomarkers as well as companion diagnostics tests has seen an outgrowth in drug discovery companies to invest in novel strategies for biomarker discovery. The industry of genome editing has witnessed some great breakthroughs during a year in the areas like genome writing, base editing and specific progression in the field of therapeutics through the Car-T cells and immunotherapy. With the increasing focus on the development of human microbiome therapies and probiotics product &drug development various small innovative players are operating in the market.
Witness an overwhelming participation of the key decision makers from academia, pharmaceutical and bio-pharmaceutical industies working in the areas of research and development, manufacturing, market access, commercialization and supply chain under one roof.
MarketsandMarkets’ Biopharma Series is a platform providing an opportunity to experts from the industry, regulators, academia and technology providers to discuss innovations, challenges, best practices, use-cases and future aspects in the area of single cell analysis, next-gen immune-oncology, next-gen bioprocessing, cell and gene therapy manufacturing, biosimilars drug development and commercialization and pharma supply chain and logistics.
Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. There are still factors like manufacturing maze, investment, logistics and regulatory challenges which prevents the cell and gene therapies to be widely used. We are once again putting together a unique platform to provide the exact solutions to these robust manufacturing and bioprocessing challenges, at our 4th Annual MarketsandMarkets Next Gen Bioprocessing Conference.
Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 23rd-24th, June 2022, in Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.
Over last several years, there has been a rapid development of technologies, methods, and applications of Single-Cell Analysis. Recent advances in single cell technologies have opened new avenues to signify the intra-tumor cell heterogeneity, identify rare cell kinds, degree of mutation, and ultimately guide diagnosis and treatment option. Single-cell sequencing is one of the most promising methods to study the tumor cells in cancer progression. These technologies have progressed intensely, and vigorously over the past five years.
With the advent of new technological advances and surgical techniques, minimally invasive surgery has witnessed a robotic revolution in the field of surgery in the form of Da Vinci robotic systems making MIS procedures a widely accepted standard of care for most of the clinical specialties all over the world.
The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
Regenerative therapies are proving its acceptance in potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.
Single-cell analysis is crucial for discovering population heterogeneity, identifying minority sub-populations of interest, and discovering unique properties of individual cells. Microfluidic systems operate on a scale comparable to cell width and are capable of manipulating single cells. Single-cell sequencing is a new and powerful technique for studying the evolution and variety of most malignancies, as well as the involvement of circulating tumour cells in cancer progression. These techniques have begun to answer critical problems in cancer biology that have been difficult to answer using bulk tumour measurements. The technology and applications of single-cell analysis have advanced dramatically in the last five years.
MarketsandMarkets is proud to announce the 5th Annual Real-World Data, Life Sciences Analytics and Market Access Conference to be held on October 20-21, 2022.
This conference will focus on above said significant challenges and hold discussion on the best practices adopted by various stakeholders with a key takeaway for better decision making.
The Biosimilars industry is experiencing significant growth due to the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. The global biosimilars market size is expected to grow from USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. However, with complexities in manufacturing and resistance from biologic manufacturers, such factors keeps adding to the hinderance in their development.
MarketsandMarkets is proud to announce the 3rd Annual MarketsandMarkets World Pharma Supply Chain and Cold Chain Logistics Conference on 20th-21st October 2022
Pharmaceutical supply chain and logistics faced the hardest disruptions during initial COVID era. Now, with COVID therapeutic manufacturing taking space, there also is a big desire to accelerate other clinical pipeline because of the ample opportunity for new medicine. While some companies were able to cope with their contingencies plan in place, the other followed risk mitigation. It is now essential for the pharma supply chain and logistics to follow the redundancy routes.
Emerging agricultural trends involve new technologies and strategies that become more advanced over time. There have been significant changes in the agriculture sector over the past several decades and new technologies have also been introduced. All these factors have led to an expansion of the sector. Recent agricultural advances have made farming activities more comfortable and acceptable for farmers. Developments or trends such as these benefit not only the growth of agriculture, but also the lives of farmers.
The Diagnostics sector has emerged as a prominent game changer in healthcare, because of many technological advancements taking place within the field. As diagnostics is a key for making the treatment decisions, it needs to be quicker, précised, and accurate.
MarketsandMarkets is extremely delighted to announce its 3rd Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference scheduled to be held on 23rd - 24th March 2022 in London.
Based on the survey on 1,000 hospitals in 33 countries, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day, one in 18 patients in a European hospital has healthcare-associated infection (HAIs). Most the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection, surgical site infection and urinary tract infection.
New medicine for Orphan and Rare Diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.
The advancement of delicate CTC and cfDNA identification led to innovations that has empowered the improvement of liquid biopsies with numerous clinical applications, including-screening for nearness of disease, patient stratification and treatment determination,monitoring treatment reaction and early diagnostics.
The treatment options for cancer, such as chemotherapies and radiation therapy, although have more side effects, are more widely used as compared to immunotherapies. The former are all based on destroying cancer cells by irradiation, chemotherapy, or surgery. While they can effectively kill or remove cancer cells, the use of these treatments is often limited because they tend to destroy healthy cells in large numbers as well. As immunotherapies involve the mechanism of enhancing the body’s own immunity using man-made proteins such as monoclonal antibodies, they are accepted worldwide over other treatment options.
In recent years, there has been an extraordinary leap in knowledge of the human genome and its role in health and disease. Advanced genetic sequencing has been revolutionizing discoveries across life sciences and has been accelerating technology that offers ultra-high throughput, scalability, and speed in modern medicine
Single-cell analysis is crucial for discovering population heterogeneity, identifying minority sub-populations of interest, and discovering unique properties of individual cells. Microfluidic systems operate on a scale comparable to cell width and are capable of manipulating single cells. Single-cell sequencing is a new and powerful technique for studying the evolution and variety of most malignancies, as well as the involvement of circulating tumour cells in cancer progression. These techniques have begun to answer critical problems in cancer biology that have been difficult to answer using bulk tumour measurements. The technology and applications of single-cell analysis have advanced dramatically in the last five years.
Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. There are still factors like manufacturing maze, investment, logistics and regulatory challenges which prevents the cell and gene therapies to be widely used. We are once again putting together a unique platform to provide the exact solutions to these robust manufacturing and bioprocessing challenges, at our 3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference.
Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress to be held on 26 - 29 October 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.
MarketsandMarkets is proud to announce the 5th Edition Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference to be held on October 20-22, 2021. The expanding utilization of Real World Evidence to speed up data driven choices is further developing the clinical trial experience, but healthcare in general.
While there is extraordinary promise in utilizing Real World Data and Real World Evidence, there are some significant challenges that should be survived: potential bias of information and data sources, inadequate data sets and absence of harmonization of data between RWE data sources, access to such data, and lack of standards in evaluating the worth of Real World Evidence data. Further developing RWE is key for pharma organizations in drug development. There was big data available pre covid and now with the access data due to covid, technology enablers like AI and ML are important for big data analysis and evidence generation. Every stakeholder has faced a some impact and had to adjust.
The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
The pandemic has disrupted healthcare systems frameworks around the world, with hospitals being overwhelmed due to the increasing influx of patients. The spread of COVID-19 has prodded a surge in demand for cleaning and disinfection products due to the growing awareness about hygiene, health, and safety. The increasing healthcare expenditure in North America being the major factor driving the demand and uptake of antiseptics and disinfectants in the region.
The utilization of reprocessed equipment to disinfect or sterilize medical devices is higher than normal now since improper decontamination of surgical instruments, endoscopic devices, respiratory care devices, and reusable hemodialysis machines can increase the chances of healthcare associated infections. Patient-to-patient pathogen transmission via medical devices can be entirely prevented by properly sterilizing medical devices.
The pandemic has disrupted healthcare systems frameworks around the world, with hospitals be-ing overwhelmed due to the increasing influx of patients. The spread of COVID-19 has prodded a surge in demand for cleaning and disinfection products due to the growing awareness about hy-giene, health, and safety.
The utilization of reprocessed equipment to disinfect or sterilize medical devices is higher than normal now since improper decontamination of surgical instruments, endoscopic devices, respira-tory care devices, and reusable hemodialysis machines can increase the chances of healthcare as-sociated infections. Patient-to-patient pathogen transmission via medical devices can be entirely prevented by properly sterilising medical devices
Nanopore sequencing and its application to pandemic epidemiological survey of SARS CoV-19 and strains surveillance. Now, with COVID therapeutic manufacturing taking priority, there is a big desire to accelerate other clinical pipeline because of ample opportunity for new medicine.
MarketsandMarkets is proud to announce the Advanced Genetic Sequencing Virtual Conference scheduled to be held on 23-24 September 2021 will hold discussions on trending technologies and its applications, challenges of implying these technologies into clinical specimen, practice of sequencing in healthcare domain specifically to cancer cells, overview of the data used in these technologies and its applications. This event will witness an overwhelming participation of leading healthcare and industry decision makers.
Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress-US Edition to be held on 28th-1st July 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.
Pharmaceutical supply chain and logistics faced the hardest disruptions during initial COVID era. Now, with COVID therapeutic manufacturing taking priority, there also is a big desire to accelerate other clinical pipeline because of the ample opportunity for new medicine. While some companies were able to cope with their contingencies plan in place, the other followed risk mitigation. It is now essential for the pharma supply chain and logistics to follow the redundancy routes.
After the successful foureditions of Bioprocessing of Cell therapies, coming up with 5th Annual of Bioprocessing of Biotherapeutics brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for the development, manufacture and quality of protein expressions, cell, and gene therapies.
The virtual event will present detailed case studies and interactive discussions in cell culture, scale-up, continuous processing, recovery, purification, process and product characterization, and formulation.
MarketsandMarkets is proud to announce the 4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference to be held on 22- 23 April, 2021.
While the 3rd annual virtual conference had discussions on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers, the 4th Annual conference will focus on discussion about the application of RWD/RWE across the life cycle. The event will discuss Impact of COVID-19 on the real-world generation and making sense of the Electronic Health Records data for COVID-19.
As per MarketsandMarkets research analysis, the global dPCR and qPCR is estimated to grow to USD 6,270.9 million by 2024 at a CAGR of 8.8%. Factors such as the rising incidences of target infectious diseases and genetic disorders; continuous technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use.
The 8th Edition Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 25 - 26 March 2021 would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data.
Based on the survey on 1,000 hospitals in 33 countries, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day, one in 18 patients in a European hospital has healthcare-associated infection (HAIs). Most the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection, surgical site infection and urinary tract infection.
One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations.
Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. Globally, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases, glaucoma, and specifically cancer have a significant impact on the health status of people worldwide, with comparatively higher growth rates in developing countries.
Witness the significant development of microbiome, probiotics and prebiotics research alongside their applications relating to difficulties like therapeutic information understanding, speculation and administrative obstacles looked by the experts. The convergence between developing innovation and disclosure with the setting of consumer intrigue. Recognize the non-distinguished dysbiosis, to find the expected territories under examination for interests in Gut and Skin microbiome and its part as an indicative instrument of drug revelation.
New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.
Single-cell sequencing (SCS) is new effective tool for investigating the evolution and variety of most cancers and role of circulating tumor cells in cancer progression. These methods have started to unravel key questions in cancer biology which have been hard to deal with for bulk tumor measurements. Over the span of 5 years, there has been exceptional development in technology and applications of Single-cell analysis.
Recent advances in single cell technologies have opened new avenues to signify the intra-tumor cell heterogeneity, identify rare cell kinds, degree of mutation, and, ultimately guide diagnosis and treatment option.
MarketsandMarkets is proud to announce the Pharma Cold Chain Logistics - Virtual Conference to be held on 5th - 6th November 2020. Increasing pressure faced by pharmaceutical companies to make their supply chain more efficient, cost effective, focused and more agile has made the industry increasingly competitive in the recent years. With the wide consumption of cold chain logistics in the pharmaceutical industry, efficient temperature controlled logistics is mandatory for quality assurance of drugs. Now with the additional road-blocks and problems due to the pandemic, the pharma supply chain is faring, specifically transportation.
Regenerative therapies are proving its acceptance in potential of cell-based therapies for chronic disorders. Since our past three editions, our aim through this conference is to provide illustrative approach to recent developments in technologies of bioprocessing of cellular therapies, to process development and addressing qualitative and regulatory hurdles.
In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.
The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
MarketsandMarkets is proud to announce the 3rd Annual Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference to be held on October 22nd -23rd, 2020.
While the 2nd annual Congress had discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation, the 3rd Annual will focus on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers.
The Biosimilars industry is experiencing significant growth due to the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness.
The global biosimilars market size is expected to grow from USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. However, with complexities in manufacturing and resistance from biologic manufacturers, such factors keeps adding to the hinderance in their development.
Point-of-care testing (POCT) is a growing technology. Today, you may see POCT in a hospital with hand held gadgets or small testers in emergency department, extensive care setting, popular clinical wards and imaging facilities. And market analyses that the world is moving from critical laboratory testing to testing for quick and accurate results at the patient's point of care.
The cytotoxic nature of HPAPIs presents significant handling challenges and thus requires heavy investments for implementing specialized containment facilities that facilitate the safety of employees from exposure. Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer.
One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations.
MarketsandMarkets is proud to announce the 4th Annual High Potent Medicines Conference to be held on 14th - 15th September 2020 . This conference would address the challenges in the continual evolution of industry standards, technologies, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations, live case studies and breakthrough panel discussions.
New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.
MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases scheduled to be held on 9th -10th July 2020 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis. Over the course of the conference, internationally-renowned speakers can describe how their analysis journeys have developed the response towards up to date challenges. The attending specialists and trade partners will offer an incredible networking expertise.
Increasing pressure faced by pharmaceutical companies to make their supply chain more efficient, cost effective, focused and more agile has made the industry increasingly competitive in the recent years. With the mandate for serialization, strict quality regulations and increasing importance of patient centricity for pharma companies to follow, it is essential to navigate from complex supply chain ecosystem to simpler processes. Now with the additional roadblocks and problems due to the pandemic (global outbreak), the pharma supply chain is faring. Major problem being the impact of COVID-19 on two of the largest global producers of active pharmaceutical ingredients (APIs) and generics: China and India.
Due to growing concerns about COVID-19, the 3rd Annual MarketsandMarkets Next Gen IO Congress is going fully virtual this year. We are disappointed that we are not able to come together in person in June for this event, but we are so thrilled to see you on an online platform. We are working together to create a virtual conference that will be beneficial and engaging for speakers, attendees and sponsors/exhibitors.
See the Post Show report of our 2nd Annual here
Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. In our conference of 2017, we assessed the specific risks and benefits of the cell culture and cell therapy bio-manufacturing for the cure of these diseases.
Witness the major breakthroughs of microbiome, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery.
See the Post Show report of our inaugural event here
As the era of personalized medicine is fast approaching, healthcare is becoming more personalized and tailored to the patient. Digital health platforms has helped converting medical data into a continuous, reliable and complete picture of the patient's health, and data analytics algorithms process information that is specific to individuals, leading to more personal and effective solutions.
MarketsandMarkets are proud to host its inaugural “Digital Transformation and Precision Medicine Virtual Conference” which will be held on 11th-12th June 2020. The conference will focus on the innovative and disruptive digital health technologies and futuristic business models transforming the precision medicine industry. The conference further aims in bringing experts from the academics, pharma, start-ups, hospitals and technology providers who will share their recent technological breakthroughs in personalized medicine.
In recent years, the understanding regarding the role of epigenetic factors has been improved. Epigenetic research has been generally determined by technological advancement, remarkably high-throughput sequencing technologies. In spite of the fact that technologies have been improved and have been responsible for the advances in the field, several challenges remain.
Our 5th Annual Epigenetics- Digital Conference will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.
The advancement of delicate CTC and cfDNA identification led to innovations that has empowered the improvement of liquid biopsies with numerous clinical applications, including-screening for nearness of disease, patient stratification and treatment determination, monitoring treatment reaction and early diagnostics.
MarketsandMarkets Virtual Conference on Liquid Biopsy will unite the pioneers from Diagnostics organization, Experts from Pharmaceutical and Bio-Pharma companies, Researchers and professors from renowned universities to address the challenges in early detection of tumor cells and the potential of liquid biopsies to screen, monitor and treatment of the diseases.
According to a study published by The Lancet Infectious Diseases, researchers estimated that globally 3 in every 1,000 people carry latent multidrug-resistant tuberculosis (MDR-TB), with the prevalence of being 10 times higher among children younger than 15 years of age.
As outlined in the independent review on Antimicrobial Resistance, AMR is predicted to kill 10 million people every year by 2050 without action. From rare pathogens to pandemic prevention, explore the latest techniques and technologies that are shaping today’s diagnosis and treatment of infectious diseases.
The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 6th - 7th February 2020 in San Diego, CA would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics areas. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.
What are the essentials being missed out on? What is the real role of probiotics strains, prebiotics and symbiotic in influencing a health? How do you standardize microbiome analysis?
Witness the major breakthroughs of microbiome, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery.
With the increasing recognition of real-world data opportunities and challenges within the pharmaceutical and biotech industry, life sciences organizations face clear decisions on how specifically to put resources into real-world evidence capacities. Real-World Evidence can possibly change the way life sciences associations use advancements to increase further clinical bits of knowledge and enable them and payers to collaborate like never before. After the successful inaugural, this year’s congress will hold discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation.
Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon. The conference will address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
Improving clinical translation in neuroscience research has always been a major challenge until now. There are many research collaborations happening in the neuroscience space today for neurodegenerative disorders research. The conference will focus on discussing the latest technologies in the preclinical, translational neuroscience space and also drawing the attention of the audience towards new innovations happening in translational neuroscience imaging. The conference further aims to bring in the experts from academia and industry together to discuss how to create new, more effective translational neuroscience drawing on novel technology and recent discoveries.
While most of the molecular studies focus over mutational analysis, epigenetics-is the only science which is gaining momentum with its cheaper and faster technology, by making its way to the clinic. Moving on the path of clinical epigenetics, this congress will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.
The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.
Drug product development for highly potent APIs (HPAPIs) can be challenging. Complications with the interface between operations in drug substance and drug product handling can result in increased program complexity and cost. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine. This year’s conference will focus on case studies related to development, rapid scaling, validation and commercial production of HPAPI drug substance, as well as integrated containment requirements for particle engineering and drug product.
Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon.
The 4th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th-8th February 2019 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.
The next big question in cancer immunotherapy is what’s next in immuneoncology?
Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.
Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors